Different outcomes for omega-3 heart trials: Why?

Current Opinion in Clinical Nutrition and Metabolic Care

Volumn 15, Issue 2, 2012, Pages 97-98

  Deckelbaum, Richard J ^a   Calder, Philip C ^b  

^a Department of Medicine   (United States)

^b UNIVERSITY OF SOUTHAMPTON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

DOCOSAHEXAENOIC ACID; LINOLEIC ACID; OMEGA 3 FATTY ACID; OMEGA 6 FATTY ACID;

CARDIOVASCULAR RISK; EDITORIAL; HEART INFARCTION; HUMAN; ISCHEMIC HEART DISEASE; META ANALYSIS (TOPIC); MORBIDITY; MORTALITY; OUTCOME ASSESSMENT; RANDOMIZED CONTROLLED TRIAL (TOPIC); RISK REDUCTION;

CORONARY DISEASE; FATTY ACIDS, OMEGA-3; HEART; HUMANS; MYOCARDIAL INFARCTION; RANDOMIZED CONTROLLED TRIALS AS TOPIC; TREATMENT OUTCOME;

EID: 84857041455     PISSN: 13631950     EISSN: 14736519     Source Type: Journal    
DOI: 10.1097/MCO.0b013e32834ec9e5     Document Type: Editorial

References (23)

1. Seo T, Blaner WS, Deckelbaum RJ. Omega-3 fatty acids: Molecular approaches to optimal biological outcomes. Curr Opin Lipidol 2005; 16:11-18. (Pubitemid 40333361)
2. Calder PC, Yaqoob P. Omega-3 polyunsaturated fatty acids and human health outcomes. Biofactors 2009; 35:266-272.
3. Chang CL, Seo T, Du CB, et al. n-3 Fatty acids decrease arterial low-density lipoprotein cholesterol delivery and lipoprotein lipase levels in insulin-resistant mice. Arterioscler Thromb Vasc Biol 2010; 30:2510-2517.
4. Saravanan P, Davidson NC, Schmidt EB, Calder PC. Cardiovascular effects of marine omega-3 fatty acids. Lancet 2010; 376:540-550.
5. Leaf A, Albert CM, Josephson M, et al. Prevention of fatal arrhythmias in highrisk subjects by fish oil n-3 fatty acid intake. Circulation 2005; 112:2762-2768. (Pubitemid 41641669)
6. Christensen JH, Gustenhoff P, Korup E, et al. Effect of fish oil on heart rate variability in survivors of myocardial infarction: A double blind randomised controlled trial. BMJ 1996; 312:677-678. (Pubitemid 26085264)
7. Thies F, Garry JM, Yaqoob P, et al. Association of n-3 polyunsaturated fatty acids with stability of atherosclerotic plaques: A randomised controlled trial. Lancet 2003; 361:477-485. (Pubitemid 36173713)
8. Cawood AL, Ding R, Napper FL, et al. Eicosapentaenoic acid (EPA) from highly concentrated n-3 fatty acid ethyl esters is incorporated into advanced atherosclerotic plaques and higher plaque EPA is associated with decreased plaque inflammation and increased stability. Atherosclerosis 2010; 212: 252-259.
9. GISSI-Prevezione. Dietary supplementation with n-3 polyunsaturated fatty acids and vitamin E after myocardial infarction: Results of the GISSIPrevenzione trial. Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto miocardico. Lancet 1999; 354:447-455.
10. Yokoyama M, Origasa H, Matsuzaki M, et al. Effects of eicosapentaenoic acid on major coronary events in hypercholesterolaemic patients (JELIS): A randomised open-label, blinded endpoint analysis. Lancet 2007; 369:1090-1098. (Pubitemid 46483662)
11. Bucher HC, Hengstler P, Schindler C, Meier G. N-3 polyunsaturated fatty acids in coronary heart disease: A meta-Analysis of randomized controlled trials. Am J Med 2002; 112:298-304. (Pubitemid 34219443)
12. Studer M, Briel M, Leimenstoll B, et al. Effect of different antilipidemic agents and diets on mortality: A systematic review. Arch Intern Med 2005; 165:725-730. (Pubitemid 40569423)
13. Leon H, Shibata MC, Sivakumaran S, et al. Effect of fish oil on arrhythmias and mortality: Systematic review. BMJ 2008; 337:a2931.
14. Wang C, Harris WS, Chung M, et al. n-3 Fatty acids from fish or fish-oil supplements, but not alpha-linolenic acid, benefit cardiovascular disease outcomes in primary-And secondary-prevention studies: A systematic review. Am J Clin Nutr 2006; 84:5-17. (Pubitemid 44699166)
15. Hooper L, Thompson RL, Harrison RA, et al. Risks and benefits of omega 3 fats for mortality, cardiovascular disease, and cancer: Systematic review. BMJ 2006; 332:752-760.
16. Kromhout D, Giltay EJ, Geleijnse JM. n-3 Fatty acids and cardiovascular events after myocardial infarction. N Engl J Med 2010; 363:2015-2026.
17. Rauch B, Schiele R, Schneider S, et al. OMEGA, a randomized, placebocontrolled trial to test the effect of highly purified omega-3 fatty acids on top of modern guideline-Adjusted therapy after myocardial infarction. Circulation 2010; 122:2152-2159.
18. Harris WS, Mozaffarian D, Rimm E, et al. Omega-6 fatty acids and risk for cardiovascular disease: A science advisory from the American Heart Association Nutrition Subcommittee of the Council on Nutrition, Physical Activity, and Metabolism; Council on Cardiovascular Nursing; and Council on Epidemiology and Prevention. Circulation 2009; 119:902-907.
19. Burr ML, Fehily AM, Gilbert JF, et al. Effects of changes in fat, fish, and fibre intakes on death and myocardial reinfarction: Diet and reinfarction trial (DART). Lancet 1989; 2:757-761. (Pubitemid 19234807)
20. De Caterina R. n-3 Fatty acids in cardiovascular disease. N Engl J Med 2011; 364:2439-2450.
21. Kris-Etherton PM, Harris WS, Appel LJ. Fish consumption, fish oil, omega-3 fatty acids, and cardiovascular disease. Arterioscler Thromb Vasc Biol 2003; 23:e20-e30.
22. Scientific Advisory Committee on Nutrition. Committee on Toxicity. Advice on fish consumption: Benefits and risks. London: The Stationary Office; 2004.
23. Elmadfa I, Kornsteiner M. Fats and fatty acid requirements for adults. Ann Nutr Metab 2009; 55:56-75.